MCID: INT080
MIFTS: 40

Intraocular Melanoma

Categories: Rare diseases, Skin diseases, Genetic diseases

Aliases & Classifications for Intraocular Melanoma

MalaCards integrated aliases for Intraocular Melanoma:

Name: Intraocular Melanoma 53 29 6
Uveal Melanoma 53 73
Melanoma of the Uvea 53

Classifications:



Summaries for Intraocular Melanoma

NIH Rare Diseases : 53 Intraocular melanoma is a cancer of the pigment-producing cells (melanocytes) in the middle layer of the eye, called the uveal tract.  The uveal tract has 3 main parts: (1) the choroid (the tissue layer filled with blood vessels); (2) the ciliary body (the ring of muscle tissue that changes the size of the pupil and the shape of the lens); and (3) the iris (the colored part of the eye). Most cases (90%) of intraocular melanoma develop in the choroid, called choroidal melanoma; the ciliary body is less commonly a site of origin, and the iris is the least common.  Each manifests with different clinical features and symptoms. Treatment depends on the site of origin (choroid, ciliary body, or iris), size and location of the tumor, the age of the individual, and other factors. 

MalaCards based summary : Intraocular Melanoma, also known as uveal melanoma, is related to melanoma, uveal and skin melanoma. An important gene associated with Intraocular Melanoma is GNAQ (G Protein Subunit Alpha Q), and among its related pathways/superpathways are Pathways in cancer and IL-2 Pathway. The drugs Ranibizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and bone, and related phenotype is pigmentation.

Related Diseases for Intraocular Melanoma

Graphical network of the top 20 diseases related to Intraocular Melanoma:



Diseases related to Intraocular Melanoma

Symptoms & Phenotypes for Intraocular Melanoma

MGI Mouse Phenotypes related to Intraocular Melanoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 pigmentation MP:0001186 8.62 GNA11 GNAQ

Drugs & Therapeutics for Intraocular Melanoma

Drugs for Intraocular Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 173)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3 347396-82-1 459903
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
3 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Not Applicable
4 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
5 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
6 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Not Applicable
8 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Not Applicable
9 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
13 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Not Applicable
14
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
15
Melphalan Approved Phase 3,Phase 2 148-82-3 4053 460612
16
Fotemustine Experimental, Investigational Phase 3
17 Alkylating Agents Phase 3,Phase 2,Phase 1
18 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
19 Vaccines Phase 3,Phase 2,Phase 1,Not Applicable
20 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
22
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
23
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
24
Sunitinib Approved, Investigational Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
25
Tamoxifen Approved Phase 2 10540-29-1 2733526
26
Bevacizumab Approved, Investigational Phase 2,Not Applicable 216974-75-3
27
Fludarabine Approved Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
28
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
29
Mesna Approved, Investigational Phase 2 3375-50-6 598
30
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
31
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
32
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
33
Iodine Approved, Investigational Phase 2,Phase 1 7553-56-2 807
34
Everolimus Approved Phase 2 159351-69-6 6442177
35
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
36
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
37
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
38
Leuprolide Approved, Investigational Phase 2 53714-56-0 3911 657181
39
Vorinostat Approved, Investigational Phase 2,Early Phase 1 149647-78-9 5311
40
Trametinib Approved Phase 2,Phase 1 871700-17-3 11707110
41
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
42
Aldesleukin Approved Phase 1, Phase 2,Phase 2 85898-30-2, 110942-02-4
43
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
44
Pancrelipase Approved, Investigational Phase 2 53608-75-6
45
Ethiodized oil Approved, Investigational Phase 2 8008-53-5
46
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
47
Somatostatin Approved, Investigational Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
48
Aluminum sulfate Approved Phase 2 10043-01-3
49
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
50
Acyclovir Approved Phase 2 59277-89-3 2022

Interventional clinical trials:

(show top 50) (show all 138)
# Name Status NCT ID Phase Drugs
1 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
2 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4 Triamcinolone Acetonide
3 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
4 Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed NCT01974752 Phase 3 75mg selumetinib;placebo;Dacarbazine
5 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
6 Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Recruiting NCT01983748 Phase 3
7 The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases Recruiting NCT01785316 Phase 3
8 Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Active, not recruiting NCT02843386 Phase 3 Adjuvant chemotherapy by Fotemustin
9 Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma Terminated NCT00110123 Phase 3 fotemustine;isolated perfusion
10 Vaccine Therapy in Treating Patients With Melanoma of the Eye Terminated NCT00036816 Phase 3
11 A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Unknown status NCT01377025 Phase 2 Placebo;Sorafenib;Sorafenib
12 A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma Unknown status NCT01551459 Phase 2 Dacarbazine;Sunitinib
13 Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye Unknown status NCT01217398 Phase 2 temozolomide
14 Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2 cisplatin;sunitinib malate;tamoxifen citrate
15 Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy Unknown status NCT02586727 Phase 2 aflibercept
16 Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma Completed NCT01979523 Phase 2 Trametinib;Uprosertib
17 Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Completed NCT01034787 Phase 2 CP-675,206
18 RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Completed NCT01252251 Phase 2 RAD001 (Everolimus) and Pasireotide (SOM230) LAR
19 Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma Completed NCT00506142 Phase 2 Marqibo® (vincristine sulfate liposomes injection)
20 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery Completed NCT00738361 Phase 2 nab-paclitaxel
21 Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Completed NCT02517736 Phase 2 Sorafenib at a dose of 800 mg / day
22 Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Completed NCT00661622 Phase 2 GM-CSF
23 Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00003339 Phase 2
24 Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye Completed NCT00329641 Phase 2 carboplatin;paclitaxel;sorafenib tosylate
25 Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01413191 Phase 2
26 Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma Completed NCT00084656 Phase 2
27 Vaccine Therapy in Treating Patients With Metastatic Melanoma Completed NCT00334776 Phase 2
28 PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma Completed NCT00238329 Phase 2 thalidomide
29 Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00027742 Phase 2 temozolomide
30 Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye Completed NCT00020475 Phase 2 gp100 antigen;interleukin-2;MART-1 antigen;Montanide ISA-51
31 Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery Completed NCT00089206 Phase 2
32 Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma Completed NCT00089219 Phase 1, Phase 2
33 Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma Completed NCT00072345 Phase 2 lomustine;temozolomide;thalidomide
34 Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma Completed NCT00003802 Phase 2 pyrazoloacridine
35 Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma Completed NCT00032045 Phase 2
36 Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma Completed NCT00031733 Phase 2 alum adjuvant
37 Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00005815 Phase 1, Phase 2 temozolomide;thalidomide
38 Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma Completed NCT00058279 Phase 1, Phase 2
39 Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01143402 Phase 2 Dacarbazine;Selumetinib;Temozolomide
40 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma Completed NCT01814046 Phase 2 Aldesleukin;Cyclophosphamide;Fludarabine
41 Melanoma Vaccine With Peptides and Leuprolide Completed NCT00254397 Phase 2 Leuprolide
42 Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma Completed NCT00085189 Phase 2 Montanide ISA 51 VG;agatolimod sodium
43 Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Completed NCT01835145 Phase 2 Cabozantinib S-malate;Dacarbazine;Temozolomide
44 AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma Completed NCT00243061 Phase 2 cediranib maleate
45 VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed NCT00450255 Phase 2
46 Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma Completed NCT00121225 Phase 2 vorinostat
47 Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Completed NCT01961115 Phase 2 Epacadostat
48 Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma Completed NCT00288041 Phase 2 carboplatin;paclitaxel;bortezomib
49 Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma Completed NCT00085306 Phase 2
50 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan

Search NIH Clinical Center for Intraocular Melanoma

Genetic Tests for Intraocular Melanoma

Genetic tests related to Intraocular Melanoma:

# Genetic test Affiliating Genes
1 Intraocular Melanoma 29

Anatomical Context for Intraocular Melanoma

MalaCards organs/tissues related to Intraocular Melanoma:

41
Eye, Liver, Bone, Testes, T Cells, Endothelial, Lung

Publications for Intraocular Melanoma

Articles related to Intraocular Melanoma:

(show top 50) (show all 64)
# Title Authors Year
1
MRI-based treatment planning and dose delivery verification for intraocular melanoma brachytherapy. ( 28818442 )
2018
2
Visualization and Quantitative 3D Analysis of Intraocular Melanoma and Its Vascularization in a Hamster Eye. ( 29364141 )
2018
3
Clinical experience of stereotactic radiosurgery at a linear accelerator for intraocular melanoma. ( 28520637 )
2017
4
Cost-effectiveness of proton beam therapy for intraocular melanoma. ( 25993284 )
2015
5
Intravitreally Injected HCmel12 Melanoma Cells Serve as a Mouse Model of Tumor Biology of Intraocular Melanoma. ( 25658144 )
2015
6
Inhibition of tumor growth by I^-elemene through downregulation of the expression of uPA, uPAR, MMP-2, and MMP-9 in a murine intraocular melanoma model. ( 25405459 )
2014
7
Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma. ( 21765463 )
2012
8
Variability of standardized echographic ultrasound using 10 mHz and high-resolution 20 mHz B scan in measuring intraocular melanoma. ( 21573095 )
2011
9
In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. ( 20713886 )
2010
10
A pilot study of vasculogenic mimicry immunohistochemical expression in intraocular melanoma model. ( 19287998 )
2009
11
Osteogenic intraocular melanoma in an alpaca (Vicugna pacos). ( 19139525 )
2009
12
Treatment of primary intraocular melanoma. ( 16613538 )
2006
13
Coexistence of pituitary adenocarcinoma and intraocular melanoma in a sheep. ( 17114384 )
2006
14
Prolonged survival after complete resection of metastases from intraocular melanoma. ( 14692032 )
2004
15
Modelling survival after treatment of intraocular melanoma using artificial neural networks and Bayes theorem. ( 14971774 )
2004
16
Prolonged survival after complete resection of metastases from intraocular melanoma. ( 15222009 )
2004
17
Reduction of liver metastasis of intraocular melanoma by interferon-beta gene transfer. ( 12824250 )
2003
18
Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. ( 12470140 )
2002
19
Intraocular melanoma spread to regional lymph nodes: report of two cases. ( 10696752 )
2000
20
Intraocular melanoma in an alpaca. ( 11397265 )
1999
21
Risk factors for intraocular melanoma and occupational exposure. ( 10502585 )
1999
22
Role of epidermal growth factor receptor in the metastasis of intraocular melanomas. ( 9620065 )
1998
23
Management of Irish patients with intraocular melanoma referred to Liverpool, England. ( 9826044 )
1998
24
Tumor vascularity and hematogenous metastasis in experimental murine intraocular melanoma. ( 10360307 )
1998
25
Unilateral exophthalmos due to orbital metastasis from a contralateral intraocular melanoma. ( 9683861 )
1998
26
Preventable delays in the treatment of intraocular melanoma in the UK. ( 8763318 )
1996
27
Anterior vs posterior intraocular melanoma. Metastatic differences in a murine model. ( 8790099 )
1996
28
Intraocular melanoma linked to occupations and chemical exposures. ( 8664402 )
1996
29
Microwave thermoradiotherapy for intraocular melanoma. ( 8638542 )
1996
30
Local resection and other conservative therapies for intraocular melanoma. ( 10150872 )
1995
31
Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma. ( 8453550 )
1993
32
[Proliferation markers, enzyme markers and oncogene expression profile of intraocular melanoma]. ( 8219645 )
1993
33
Prevention of metastasis of intraocular melanoma in mice treated with difluoromethylornithine. ( 1547972 )
1992
34
Evaluation of closed loop control of arterial pressure during hypotensive anaesthesia for local resection of intraocular melanoma. ( 1467105 )
1992
35
Morphologic effects of bacteriochlorin a and light in vivo on intraocular melanoma. ( 1894468 )
1991
36
Management of exudative retinal detachment after plaque therapy for intraocular melanoma. ( 1882929 )
1991
37
Echographic differentiation of histological types of intraocular melanoma. ( 2053209 )
1991
38
Mouse model of brachytherapy in consort with enucleation for treatment of malignant intraocular melanoma. ( 2350289 )
1990
39
Management of intraocular melanoma. ( 2203470 )
1990
40
Photodynamic therapy for experimental intraocular melanoma using chloroaluminum sulfonated phthalocyanine. ( 2730407 )
1989
41
Experimental model for metastasis of intraocular melanoma: preventive role of natural killer cells. ( 2733256 )
1989
42
A simple cytologic method for predicting the malignant potential of intraocular melanoma. ( 2696944 )
1989
43
Congenital intraocular melanoma in a calf. ( 2794149 )
1989
44
Interval-by-interval Cox model analysis of 3680 cases of intraocular melanoma shows a decline in the prognostic value of size and cell type over time after tumor excision. ( 3338025 )
1988
45
A method for determining the optimum transform for covariates of the Cox model with application to 3680 cases of intraocular melanoma. ( 3180746 )
1988
46
Detection and quantification of S-100 protein in ocular tissues and fluids from patients with intraocular melanoma. ( 3207666 )
1988
47
Intraocular melanoma with multiple metastases in a cat. ( 3343189 )
1988
48
Reduction of enucleation-induced metastasis in intraocular melanoma by periorbital irradiation. ( 3632444 )
1987
49
Role of natural killer cells in intraocular melanoma metastasis. ( 3957568 )
1986
50
Sunlight and intraocular melanoma. ( 3951496 )
1986

Variations for Intraocular Melanoma

ClinVar genetic disease variations for Intraocular Melanoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 GNAQ NM_002072.4(GNAQ): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh37 Chromosome 9, 80409488: 80409488
2 GNAQ NM_002072.4(GNAQ): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh38 Chromosome 9, 77794572: 77794572
3 GNAQ NM_002072.4(GNAQ): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh37 Chromosome 9, 80409488: 80409488
4 GNAQ NM_002072.4(GNAQ): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh38 Chromosome 9, 77794572: 77794572
5 GNA11 NM_002067.4(GNA11): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh37 Chromosome 19, 3118942: 3118942
6 GNA11 NM_002067.4(GNA11): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh38 Chromosome 19, 3118944: 3118944
7 GNA11 NM_002067.4(GNA11): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh37 Chromosome 19, 3118942: 3118942
8 GNA11 NM_002067.4(GNA11): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh38 Chromosome 19, 3118944: 3118944
9 GNAQ NM_002072.4(GNAQ): c.625_626delCAinsTT (p.Gln209Leu) indel Likely pathogenic rs1057519853 GRCh37 Chromosome 9, 80409488: 80409489
10 GNAQ NM_002072.4(GNAQ): c.625_626delCAinsTT (p.Gln209Leu) indel Likely pathogenic rs1057519853 GRCh38 Chromosome 9, 77794572: 77794573

Expression for Intraocular Melanoma

Search GEO for disease gene expression data for Intraocular Melanoma.

Pathways for Intraocular Melanoma

Pathways related to Intraocular Melanoma according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1 12.35 GNA11 GNAQ
2
Show member pathways
12.31 GNA11 GNAQ
3
Show member pathways
12.26 GNA11 GNAQ
4
Show member pathways
12.2 GNA11 GNAQ
5 12.15 GNA11 GNAQ
6
Show member pathways
12.09 GNA11 GNAQ
7
Show member pathways
11.96 GNA11 GNAQ
8
Show member pathways
11.92 GNA11 GNAQ
10
Show member pathways
11.85 GNA11 GNAQ
11
Show member pathways
11.77 GNA11 GNAQ
12 11.66 GNA11 GNAQ
13
Show member pathways
11.64 GNA11 GNAQ
14
Show member pathways
11.62 GNA11 GNAQ
15
Show member pathways
11.58 GNA11 GNAQ
16 11.54 GNA11 GNAQ
17 11.46 GNA11 GNAQ
18 11.43 GNA11 GNAQ
19 11.38 GNA11 GNAQ
20 11.22 GNA11 GNAQ
21 11.15 GNA11 GNAQ
22 11.03 GNA11 GNAQ
23 10.91 GNA11 GNAQ
24 10.85 GNA11 GNAQ
25 10.7 GNA11 GNAQ
26 10.49 GNA11 GNAQ
27
Show member pathways
9.83 GNA11 GNAQ

GO Terms for Intraocular Melanoma

Cellular components related to Intraocular Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lysosomal membrane GO:0005765 9.16 GNA11 GNAQ
2 photoreceptor outer segment GO:0001750 8.96 GNA11 GNAQ
3 heterotrimeric G-protein complex GO:0005834 8.62 GNA11 GNAQ

Biological processes related to Intraocular Melanoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.49 GNA11 GNAQ
2 skeletal system development GO:0001501 9.48 GNA11 GNAQ
3 platelet activation GO:0030168 9.46 GNA11 GNAQ
4 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.43 GNA11 GNAQ
5 action potential GO:0001508 9.4 GNA11 GNAQ
6 G-protein coupled acetylcholine receptor signaling pathway GO:0007213 9.37 GNA11 GNAQ
7 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.32 GNA11 GNAQ
8 developmental pigmentation GO:0048066 9.26 GNA11 GNAQ
9 phototransduction, visible light GO:0007603 9.16 GNA11 GNAQ
10 entrainment of circadian clock GO:0009649 8.96 GNA11 GNAQ
11 regulation of melanocyte differentiation GO:0045634 8.62 GNA11 GNAQ

Molecular functions related to Intraocular Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GTP binding GO:0005525 9.4 GNA11 GNAQ
2 obsolete signal transducer activity GO:0004871 9.37 GNA11 GNAQ
3 GTPase activity GO:0003924 9.32 GNA11 GNAQ
4 G-protein coupled receptor binding GO:0001664 9.26 GNA11 GNAQ
5 G-protein beta/gamma-subunit complex binding GO:0031683 9.16 GNA11 GNAQ
6 guanyl nucleotide binding GO:0019001 8.96 GNA11 GNAQ
7 type 2A serotonin receptor binding GO:0031826 8.62 GNA11 GNAQ

Sources for Intraocular Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....